Evidence map›Paper›PMID 29208398›Full record

ReviewThe Lancet. Oncology2017

Future cancer research priorities in the USA: a Lancet Oncology Commission.

Elizabeth M Jaffee, Chi Van Dang, David B Agus, Brian M Alexander, Kenneth C Anderson, Alan Ashworth, Anna D Barker, Roshan Bastani, Sangeeta Bhatia, Jeffrey A Bluestone and 44 more

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in The Lancet. Oncology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 93 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
93citing papers in PubMed, 3 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

93 citing papers in PubMed, 3 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Article
  6. Article
  7. Review
  8. Article
  9. Review
  10. Review
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. [The Role of Fasting-Mimicking Diet in Cancer Therapy: Mechanisms, Challenges, and Clinical Prospects].Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition · 2025
    Review
  18. Article
  19. Review
  20. Review

33 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

54 authors.

Elizabeth M JaffeeThe Johns Hopkins University School of Medicine, Baltimore, MD, USA. Electronic address: ejaffee@jhmi.edu.
Chi Van DangLudwig Institute for Cancer Research New York, NY; Wistar Institute, Philadelphia, PA, USA. Electronic address: cdang@licr.org.
David B AgusUniversity of Southern California, Beverly Hills, CA, USA.
Brian M AlexanderDana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
Kenneth C AndersonDana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
Alan AshworthUniversity of California San Francisco, San Francisco, CA, USA.
Anna D BarkerArizona State University, Tempe, AZ, USA.
Roshan BastaniFielding School of Public Health and the Jonsson Comprehensive Cancer Center, University of California, Los Angeles, CA, USA.
Sangeeta BhatiaKoch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, USA.
Jeffrey A BluestoneUniversity of California San Francisco, San Francisco, CA, USA; Parker Institute for Cancer Immunotherapy, San Francisco, CA, USA.
Otis BrawleyAmerican Cancer Society, Atlanta, GA, USA.
Atul J ButteUniversity of California San Francisco, San Francisco, CA, USA.
Daniel G CoitDepartment of Surgery, Memorial Sloan-Kettering Cancer Center, New York, NY, USA.
Nancy E DavidsonFred Hutchinson Cancer Research Center and University of Washington, Seattle, WA, USA.
Mark DavisCalifornia Institute for Technology, Pasadena, CA, USA.
Ronald A DePinhoUniversity of Texas MD Anderson Cancer Center, Houston, TX, USA.
Robert B DiasioMayo Clinic Cancer Center, Rochester, MN, USA.
Giulio DraettaUniversity of Texas MD Anderson Cancer Center, Houston, TX, USA.
A Lindsay FrazierDana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
Andrew FutrealUniversity of Texas MD Anderson Cancer Center, Houston, TX, USA.
Sam S GambhirStanford University, Stanford, CA, USA.
Patricia A GanzFielding School of Public Health and the Jonsson Comprehensive Cancer Center, University of California, Los Angeles, CA, USA.
Levi GarrawayDana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA; The Broad Institute, Cambridge, MA, USA; Eli Lilly and Company, Boston, MA, USA.
Stanton GersonCase Comprehensive Cancer Center, Cleveland, OH, USA.
Sumit GuptaDivision of Haematology/Oncology, Hospital for Sick Children, Faculty of Medicine and IHPME, University of Toronto, Toronto, Canada.
James HeathCalifornia Institute for Technology, Pasadena, CA, USA.
Ruth I HoffmanAmerican Childhood Cancer Organization, Beltsville, MD, USA.
Cliff HudisBreast Cancer Medicine Service, Memorial Sloan-Kettering Cancer Center, New York, NY, USA.
Chanita Hughes-HalbertMedical University of South Carolina and the Hollings Cancer Center, Charleston, SC, USA.
Ramy IbrahimParker Institute for Cancer Immunotherapy, San Francisco, CA, USA.
Hossein JadvarKeck School of Medicine, University of Southern California, Los Angeles, CA, USA.
Brian KavanaghDepartment of Radiation Oncology, University of Colorado, Denver, CO, USA.
Rick KittlesCollege of Medicine, University of Arizona, Tucson, AZ, USA; University of Arizona Cancer Center, University of Arizona, Tucson, AZ, USA.
Quynh-Thu LeStanford University, Stanford, CA, USA.
Scott M LippmanUniversity of California San Diego Moores Cancer Center, University of California San Diego, La Jolla, CA, USA.
David MankoffDepartment of Radiology and Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Elaine R MardisThe Institute for Genomic Medicine at Nationwide Children's Hospital Columbus, OH, USA; College of Medicine, Ohio State University, Columbus, OH, USA.
Deborah K MayerUniversity of North Carolina Lineberger Cancer Center, Chapel Hill, NC, USA.
Kelly McMastersThe Hiram C Polk Jr MD Department of Surgery, University of Louisville School of Medicine, Louisville, KY, USA.
Neal J MeropolFlatiron Health, New York, NY, USA.
Beverly MitchellStanford University, Stanford, CA, USA.
Peter NarediDepartment of Surgery, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
Dean OrnishUniversity of California San Francisco, San Francisco, CA, USA.
Timothy M PawlikDepartment of Surgery, Wexner Medical Center, Ohio State University, Columbus, OH, USA.
Jeffrey PeppercornMassachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
Martin G PomperThe Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Derek RaghavanLevine Cancer Institute, Carolinas HealthCare, Charlotte, NC, USA.
Christine RitchieUniversity of California San Francisco, San Francisco, CA, USA.
Sally W SchwarzMallinckrodt Institute of Radiology, Washington University School of Medicine, St Louis, MO, USA.
Richard SullivanKing's College London, London, UK.
Richard WahlMallinckrodt Institute of Radiology, Washington University School of Medicine, St Louis, MO, USA.
Jedd D WolchokLudwig Center for Cancer Immunotherapy, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY, USA; Parker Institute for Cancer Immunotherapy, San Francisco, CA, USA.
Sandra L WongDepartment of Surgery, The Geisel School of Medicine at Dartmouth, Lebanon, NH, USA.
Alfred YungUniversity of Texas MD Anderson Cancer Center, Houston, TX, USA.

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI SELWYN M VICKERS · 1985 to 2026
$347.4M
Translational Research Central ServicesP30CA006973 · NCI · JOHNS HOPKINS UNIVERSITY · PI ALAN KEITH MEEKER · 1985 to 2026
$208.6M
Stanford and Northrop Grumman proposal for the Oncology Models ForumU24CA195858 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI BUTTE, ATUL J · 2015 to 2019
$4.7M
NCI NIH HHS P30 CA006973NCI NIH HHS P30 CA008748NCI NIH HHS U24 CA195858
6 · The paper itself

Abstract

We are in the midst of a technological revolution that is providing new insights into human biology and cancer. In this era of big data, we are amassing large amounts of information that is transforming how we approach cancer treatment and prevention. Enactment of the Cancer Moonshot within the 21st Century Cures Act in the USA arrived at a propitious moment in the advancement of knowledge, providing nearly US$2 billion of funding for cancer research and precision medicine. In 2016, the Blue Ribbon Panel (BRP) set out a roadmap of recommendations designed to exploit new advances in cancer diagnosis, prevention, and treatment. Those recommendations provided a high-level view of how to accelerate the conversion of new scientific discoveries into effective treatments and prevention for cancer. The US National Cancer Institute is already implementing some of those recommendations. As experts in the priority areas identified by the BRP, we bolster those recommendations to implement this important scientific roadmap. In this Commission, we examine the BRP recommendations in greater detail and expand the discussion to include additional priority areas, including surgical oncology, radiation oncology, imaging, health systems and health disparities, regulation and financing, population science, and oncopolicy. We prioritise areas of research in the USA that we believe would accelerate efforts to benefit patients with cancer. Finally, we hope the recommendations in this report will facilitate new international collaborations to further enhance global efforts in cancer control.

Indexed as

Health PrioritiesBiomedical ResearchForecastingHealth PlanningHumansMedical OncologyNational Cancer Institute (U.S.)NeoplasmsPrecision MedicineUnited States

Identifiers

PMID29208398
PMCPMC6178838

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.